Copyright Reports & Markets. All rights reserved.

Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Oral Medications
      • 1.4.3 Temozolomide
      • 1.4.4 Radiosensitizers
      • 1.4.5 Nitrosoureas Drugs
      • 1.4.6 Radiation Therapy
      • 1.4.7 Chemotherapy
    • 1.5 Market by Application
      • 1.5.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2014-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Clinics
      • 1.5.4 Ambulatory Surgical Centers
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size
    • 2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Growth Trends by Regions
      • 2.2.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions (2014-2025)
      • 2.2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Manufacturers
      • 3.1.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players Head office and Area Served
    • 3.3 Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Product/Solution/Service
    • 3.4 Date of Enter into Recurrent Glioblastoma Multiforme (GBM) Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2014-2019)
    • 4.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2014-2019)
    • 5.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in United States
    • 5.3 United States Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
    • 5.4 United States Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application

    6 Europe

    • 6.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2014-2019)
    • 6.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in Europe
    • 6.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
    • 6.4 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application

    7 China

    • 7.1 China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2014-2019)
    • 7.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in China
    • 7.3 China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
    • 7.4 China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application

    8 Japan

    • 8.1 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2014-2019)
    • 8.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in Japan
    • 8.3 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
    • 8.4 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2014-2019)
    • 9.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in Southeast Asia
    • 9.3 Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
    • 9.4 Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application

    10 India

    • 10.1 India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2014-2019)
    • 10.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in India
    • 10.3 India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
    • 10.4 India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2014-2019)
    • 11.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players in Central & South America
    • 11.3 Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
    • 11.4 Central & South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application

    12 International Players Profiles

    • 12.1 Astrazeneca
      • 12.1.1 Astrazeneca Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
      • 12.1.4 Astrazeneca Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2014-2019)
      • 12.1.5 Astrazeneca Recent Development
    • 12.2 Roche
      • 12.2.1 Roche Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
      • 12.2.4 Roche Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2014-2019)
      • 12.2.5 Roche Recent Development
    • 12.3 GlaxoSmithKline
      • 12.3.1 GlaxoSmithKline Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
      • 12.3.4 GlaxoSmithKline Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2014-2019)
      • 12.3.5 GlaxoSmithKline Recent Development
    • 12.4 Merck
      • 12.4.1 Merck Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
      • 12.4.4 Merck Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2014-2019)
      • 12.4.5 Merck Recent Development
    • 12.5 Pfizer
      • 12.5.1 Pfizer Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
      • 12.5.4 Pfizer Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2014-2019)
      • 12.5.5 Pfizer Recent Development
    • 12.6 AngioChem
      • 12.6.1 AngioChem Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
      • 12.6.4 AngioChem Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2014-2019)
      • 12.6.5 AngioChem Recent Development
    • 12.7 Vascular Biogeneics
      • 12.7.1 Vascular Biogeneics Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
      • 12.7.4 Vascular Biogeneics Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2014-2019)
      • 12.7.5 Vascular Biogeneics Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Recurrent glioblastoma multiforme is the most aggressive cancer that begins within the brain.
      The increasing incidence of seizure is expected to drive the recurrent glioblastoma multiforme treatment market.
      In 2018, the global Recurrent Glioblastoma Multiforme (GBM) Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Recurrent Glioblastoma Multiforme (GBM) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Recurrent Glioblastoma Multiforme (GBM) Treatment development in United States, Europe and China.

      The key players covered in this study
      Astrazeneca
      Roche
      GlaxoSmithKline
      Merck
      Pfizer
      AngioChem
      Vascular Biogeneics
      ...

      Market segment by Type, the product can be split into
      Oral Medications
      Temozolomide
      Radiosensitizers
      Nitrosoureas Drugs
      Radiation Therapy
      Chemotherapy

      Market segment by Application, split into
      Hospitals
      Clinics
      Ambulatory Surgical Centers

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Recurrent Glioblastoma Multiforme (GBM) Treatment status, future forecast, growth opportunity, key market and key players.
      To present the Recurrent Glioblastoma Multiforme (GBM) Treatment development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Recurrent Glioblastoma Multiforme (GBM) Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now